The best and worst funds of Q1
1 Apr 15
Although 2015 has been touted as the year of the stock picker, it would seem from the performance rankings that much of the success in the first quarter has been heavily influenced by geography and large macro swings.
Pictet Biotech Fund
A sub-fund of Pictet’s Luxembourg SICAV, the fund invests in medical biotech firms, the vast majority of which are in Europe and the US. Run by Michael Sjostrom since 1995, the fund is a consistent outperformer. Over the three months it produced a return of 22.6%, while over five years it has grown 171.2%.
